Cantargia successfully produces GMP batch of CAN04 in the 2,000 litre scale.

NORDIC BUSINESS REPORT-February 17, 2020-Cantargia successfully produces GMP batch of CAN04 in the 2,000 litre scale

(C)2020 M2 COMMUNICATIONS http://www.m2.com

Cantargia AB (STO: CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Friday that it has reached an important milestone in the development of its antibody project CAN04, with the first GMP batch of CAN04 in the 2,000 -litre scale.

Currently, CAN04 is in clinical phase IIa studies for cancer treatment, especially for non-small cell lung cancer and pancreatic cancer. This upscaling implies that Cantargia secures production methodology for later stage clinical trials with CAN04 and towards commercial manufacturing.

Reportedly, the development of the CAN04 antibody is advancing and recently communicated data suggest a synergistic effect with chemotherapy. These interim data were part of an ongoing phase IIa...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT